ALK and non-small cell lung carcinoma: In the global phase 3 ALTA-1L trial (NCT02737501), the primary endpoint, PFS, favored brigatinib compared with crizotinib in patients with TKI-naive ALK+ NSCLC (hazard ratio, 0.48 [95% confidence interval (CI), 0.35–0.66]; P < 0.0001) [6].